All three of our cancer immunotherapy stocks made major announcements recently, but its still too soon to say which one will end up being the big winner. Read More
Jim Pearce is the Chief Investment Strategist of Personal Finance, our flagship publication, and manages two trading services, PF Pro and Mayhem Trader. He began his career as a stockbroker in 1983 and over the years has managed client investment portfolios for major banks, brokerage firms, and investment advisors. Jim earned a BA from The College of William & Mary and the CFP designation from the College of Financial Planning.
Analyst Articles
Juno Therapeutics (JUNO) announced this morning that it has halted its mid-stage trial study on JCAR015, a leukemia treatment that has resulted in the death of two participants in the study group. At this time there is not enough information available to determine the extent to which this development… Read More
While most investors have been fixated on the outcome of the Brexit vote over the past ten days, there was good news regarding a couple of the “Top Tech Takeover Targets” that I identified in our most recent issue of Breakthrough Tech Profits. Read More
In only one week the reaction to Britain’s vote to exit the European Union seems to have reversed course, swinging from shock to apathy. Despite dropping more than 5% in the two trading days immediately following the vote, the S&P 500 Index mostly recovered during the next three trading days… Read More
While the rest of the world was focused on the outcome of the “Brexit” vote last week, a couple of our Special Situations Portfolio stocks reported good news that may have been overlooked. Along with the overall decline in the stock market as a result of Great Britain’s decisions to… Read More
Despite its erratic trading behavior, thus far Argos has lived up to our expectations in terms of achieving its business objectives. And with an additional $30 million in cash to fund its operations, we see no reason to change our long term view on the company’s growth prospects. Read More
- June 17, 2016
-
Download Issue
For the first time since this portfolio was launched 18 months ago, our group of Inflation Hedges holdings posted positive returns over a three-month period. From February 29 through May 31, the Inflation Hedges Portfolio posted an average gain of 9.7% versus 9.2% for the S&P 500. Leading the way… Read More
- June 17, 2016
-
Download Issue
We show you how to find them, and recommend two. Read More
- June 17, 2016
-
Download Issue
Profit from turnarounds, acquisitions and trends. Read More
Argos Therapeutics (ARGS), a clinical research stage biotech company focusing on the personalized treatment of various cancers based on rallying the individual’s own immune system through its proprietary Arcelis platform, released interim test results this morning on the company’s ongoing Phase 3 ADAPT trial of its AGS-003 compound which met… Read More